Home  |  Contact

Cellosaurus 2102EP (CVCL_C522)

Cell line name 2102EP
Synonyms 2102Ep; 2102 Ep; 2,102 Ep
Accession CVCL_C522
Resource Identification Initiative To cite this cell line use: 2102EP (RRID:CVCL_C522)
Comments Omics: Array-based CGH.
Omics: Deep quantitative proteome analysis.
Omics: SNP array analysis.
Derived from site: In situ; Testis; UBERON=UBERON_0000473.
Disease Embryonal carcinoma (NCIt: C3752)
Embryonal carcinoma (ORDO: Orphanet_180226)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_C0QK (2102EP-R)CVCL_3037 (N2102Ep Clone 2/A6)CVCL_1Q49 (PC21A1)
Originate from same individual CVCL_C523 ! 2102ER
Sex of cell Male
Age at sampling 23Y
Category Cancer cell line
Publications

PubMed=6169654; DOI=10.1002/ijc.2910260304
Andrews P.W., Bronson D.L., Benham F.J., Strickland S., Knowles B.B.
A comparative study of eight cell lines derived from human testicular teratocarcinoma.
Int. J. Cancer 26:269-280(1980)

PubMed=7471097
Wang N., Trend B., Bronson D.L., Fraley E.E.
Nonrandom abnormalities in chromosome 1 in human testicular cancers.
Cancer Res. 40:796-802(1980)

PubMed=7095898; DOI=10.1002/ijc.2910290507
Andrews P.W., Goodfellow P.N., Shevinsky L.H., Bronson D.L., Knowles B.B.
Cell-surface antigens of a clonal human embryonal carcinoma cell line: morphological and antigenic differentiation in culture.
Int. J. Cancer 29:523-531(1982)

PubMed=17284651; DOI=10.1634/stemcells.2006-0236
Josephson R., Ording C.J., Liu Y., Shin S., Lakshmipathy U., Toumadje A., Love B., Chesnut J.D., Andrews P.W., Rao M.S., Auerbach J.M.
Qualification of embryonal carcinoma 2102Ep as a reference for human embryonic stem cell research.
Stem Cells 25:437-446(2007)

PubMed=20428235; DOI=10.1371/journal.pone.0010263
Hovatta O., Jaconi Devaud M.E.E., Tohonen V., Sloan-Bena F., Gimelli S., Bosman A.G., Holm F., Wyder S., Zdobnov E.M., Irion O., Andrews P.W., Antonarakis S.E., Zucchelli M., Kere J., Feki A.
A teratocarcinoma-like human embryonic stem cell (hESC) line and four hESC lines reveal potentially oncogenic genomic changes.
PLoS ONE 5:E10263-E10263(2010)

PubMed=24812411; DOI=10.1158/1078-0432.CCR-13-2868
Feldman D.R., Iyer G., Van Alstine L., Patil S., Al-Ahmadie H., Reuter V.E., Bosl G.J., Chaganti R.S.K., Solit D.B.
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Clin. Cancer Res. 20:3712-3720(2014)

PubMed=35084545; DOI=10.1007/s00345-022-03936-1
Fichtner A., Bohnenberger H., Elakad O., Richter A., Lenz C., Oing C., Strobel P., Kueffer S., Nettersheim D., Bremmer F.
Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.
World J. Urol. 40:373-383(2022)

Cross-references
Anatomy/cell type resources BTO; BTO:0005287
Encyclopedic resources Wikidata; Q54583213
Experimental variables resources EFO; EFO_0002957
Polymorphism and mutation databases Cosmic; 2077185
Cosmic; 2163762
Proteomic databases PRIDE; PXD030251
Entry history
Entry creation22-Oct-2012
Last entry update30-Jan-2024
Version number17